Deutsche Bank’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.68M | Buy |
349,522
+129,691
| +59% | +$888K | ﹤0.01% | 1622 |
|
|
2025
Q4 | $435K | Buy |
219,831
+33,520
| +18% | +$75.9K | ﹤0.01% | 2644 |
|
|
2025
Q3 | $458K | Buy |
186,311
+27,749
| +18% | +$71.5K | ﹤0.01% | 2592 |
|
|
2025
Q2 | $419K | Buy |
158,562
+47,127
| +42% | +$127K | ﹤0.01% | 2543 |
|
|
2025
Q1 | $335K | Sell |
111,435
-11,622
| -9% | -$35.2K | ﹤0.01% | 2693 |
|
|
2024
Q4 | $315K | Sell |
123,057
-210,462
| -63% | -$877K | ﹤0.01% | 2884 |
|
|
2024
Q3 | $1.24M | Buy |
333,519
+154,378
| +86% | +$714K | ﹤0.01% | 2019 |
|
|
2024
Q2 | $1.13M | Buy |
179,141
+118,833
| +197% | +$783K | ﹤0.01% | 1928 |
|
|
2024
Q1 | $324K | Sell |
60,308
-89,417
| -60% | -$405K | ﹤0.01% | 2563 |
|
|
2023
Q4 | $752K | Buy |
149,725
+95,988
| +179% | +$301K | ﹤0.01% | 2177 |
|
|
2023
Q3 | $90.8K | Hold |
53,737
| – | – | ﹤0.01% | 3202 |
|
|
2023
Q2 | $149K | Sell |
53,737
-2,512
| -4% | -$7.1K | ﹤0.01% | 3049 |
|
|
2023
Q1 | $102K | Buy |
56,249
+14,874
| +36% | +$46.2K | ﹤0.01% | 3314 |
|
|
2022
Q4 | $210K | Sell |
41,375
-14,301
| -26% | -$78.5K | ﹤0.01% | 2950 |
|
|
2022
Q3 | $277K | Buy |
55,676
+13,799
| +33% | +$62.9K | ﹤0.01% | 2742 |
|
|
2022
Q2 | $156K | Buy |
41,877
+3,337
| +9% | +$13.4K | ﹤0.01% | 3304 |
|
|
2022
Q1 | $216K | Sell |
38,540
-4,270
| -10% | -$26.2K | ﹤0.01% | 3223 |
|
|
2021
Q4 | $260K | Sell |
42,810
-1,135
| -3% | -$8.53K | ﹤0.01% | 3239 |
|
|
2021
Q3 | $428K | Sell |
43,945
-427
| -1% | -$4.7K | ﹤0.01% | 3147 |
|
|
2021
Q2 | $634K | Buy |
44,372
+21,414
| +93% | +$354K | ﹤0.01% | 3066 |
|
|
2021
Q1 | $545K | Sell |
22,958
-529
| -2% | -$13.7K | ﹤0.01% | 3041 |
|
|
2020
Q4 | $314K | Buy |
23,487
+5,927
| +34% | +$57K | ﹤0.01% | 3200 |
|
|
2020
Q3 | $122K | Buy |
17,560
+2,950
| +20% | +$29.4K | ﹤0.01% | 3453 |
|
|
2020
Q2 | $179K | Sell |
14,610
-18,792
| -56% | -$106K | ﹤0.01% | 3192 |
|
|
2020
Q1 | $96K | Buy |
+33,402
| New | +$167K | ﹤0.01% | 3270 |
|
|
2019
Q3 | – | Sell |
-7,212
| Closed | -$7K | – | 5070 |
|
|
2019
Q2 | $7K | Sell |
7,212
-27,644
| -79% | -$31.9K | ﹤0.01% | 5039 |
|
|
2019
Q1 | $54K | Sell |
34,856
-114,474
| -77% | -$144K | ﹤0.01% | 4525 |
|
|
2018
Q4 | $172K | Buy |
149,330
+74,299
| +99% | +$170K | ﹤0.01% | 3956 |
|
|
2018
Q3 | $278K | Sell |
75,031
-2,422
| -3% | -$7.66K | ﹤0.01% | 4090 |
|
|
2018
Q2 | $237K | Buy |
77,453
+30,470
| +65% | +$113K | ﹤0.01% | 4209 |
|
|
2018
Q1 | $181K | Sell |
46,983
-20,864
| -31% | -$91.5K | ﹤0.01% | 4241 |
|
|
2017
Q4 | $304K | Buy |
67,847
+36,542
| +117% | +$173K | ﹤0.01% | 3831 |
|
|
2017
Q3 | $170K | Sell |
31,305
-7,575
| -19% | -$46.7K | ﹤0.01% | 3959 |
|
|
2017
Q2 | $294K | Sell |
38,880
-111,261
| -74% | -$481K | ﹤0.01% | 3727 |
|
|
2017
Q1 | $532K | Buy |
150,141
+137,808
| +1,117% | +$681K | ﹤0.01% | 3049 |
|
|
2016
Q4 | $69K | Sell |
12,333
-6,700
| -35% | -$44.7K | ﹤0.01% | 4240 |
|
|
2016
Q3 | $147K | Sell |
19,033
-9,981
| -34% | -$74.6K | ﹤0.01% | 3791 |
|
|
2016
Q2 | $179K | Sell |
29,014
-69,385
| -71% | -$539K | ﹤0.01% | 3831 |
|
|
2016
Q1 | $807K | Sell |
98,399
-35,720
| -27% | -$337K | ﹤0.01% | 2940 |
|
|
2015
Q4 | $2.32M | Buy |
134,119
+105,854
| +375% | +$1.57M | ﹤0.01% | 2333 |
|
|
2015
Q3 | $323K | Buy |
+28,265
| New | +$617K | ﹤0.01% | 3599 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Deutsche Bank's IBRX Position: Q1 2026 in Review
Deutsche Bank increased its ImmunityBio (IBRX) stake by 59% in Q1 2026, buying an estimated $888K and bringing the position to 349,522 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1622.
Deutsche Bank first reported a position in IBRX in Q3 2015 and has held it in 41 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Deutsche Bank held 349,522 shares of ImmunityBio worth $2.68M as of Q1 2026.
- Deutsche Bank bought 129,691 ImmunityBio shares in Q1 2026, an estimated $888K.
- ImmunityBio made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1622 holding.
- Deutsche Bank first reported a position in ImmunityBio in Q3 2015 and has held it in 41 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.